|Product/Product Candidate||Indication||Phase 1||Phase 2||Phase 3||Filing||Market|
(daptomycin for injection)
|Complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bacteremia (SAB)*|
|Clostridium difficile-associated diarrhea (CDAD)*|
|Accelerated GI recovery following surgeries that include partial bowel resection with primary anastomosis*|
|Acute bacterial skin and skin structure infections (ABSSSI)*+|
|Tedizolid phosphate||Hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP)**|
|Ceftolozane/tazobactam||Complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)**Λ|
|Hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP)**|
|Surotomycin||Clostridium difficile-associated diarrhea (CDAD)**|
* Indications for approved therapies.
** Potential indications sought pending outcome of clinical trials and regulatory approval applications for pipeline candidates.
+ Approved in the U.S. for acute bacterial skin and skin structure infections (ABSSSI); in Europe the Marketing Authorization Application filed for complicated skin and soft tissue infections (cSSTI) is under review.
Λ U.S.: PDUFA December 21, 2014.
Information updated as of June 20, 2014.